Forest to acquire Clinical Data Inc to add antidepressant Viibryd to portfolio
This article was originally published in Scrip
Executive Summary
Forest Laboratories has entered into a definitive merger agreement to acquire Clinical Data Inc for $30 per share in cash, plus a contingent value (CVR) right worth up to $6 per share based on sales performance milestones of Clinical Data's first-of-its-kind antidepressant Viibryd (vilazodone HCl), which gained FDA approval on 24 January. The CVR is meant to allow the acquiring company to mitigate long-term risk.